Sugi Predict

Sugi Predict / Compounds / SCHEMBL5264791

SCHEMBL5264791

SCHEMBL5264791

Cc1c(F)cccc1C(=O)N(C1CCCC1)[C@H]1CCN(C(=O)O)C1C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 8/20 0.38
▸ SLC6A4 P31645 8/20 0.38
▸ SLC6A3 Q01959 4/20 0.38
▸ ESR1 P03372 1/20 0.37
▸ ESR2 Q92731 1/20 0.37
▸ OPRM1 P35372 1/20 0.34
▸ ACKR3 P25106 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33
▸ TAS1R2 Q8TE23 1/20 0.33
▸ KCNH2 Q12809 2/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ PDE2A O00408 1/20 0.31
▸ UBE2M P61081 1/20 0.31
▸ DCUN1D1 Q96GG9 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HCRTR1 O43613 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887892 0.99 SLC6A2 (0.37) SLC6A2SLC6A4SLC6A3ESR1ESR2
SCHEMBL5887717 0.90 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3OPRM1KCNH2
SCHEMBL5888146 0.89 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3OPRM1GAA
SCHEMBL5200972 0.88 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3ACKR3TAS1R3
SCHEMBL5887848 0.84 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3
SCHEMBL5232639 0.83 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3KCNH2HSD11B1
SCHEMBL5229719 0.82 HPGD (0.49) SLC6A2SLC6A4SLC6A3SMN1; SMN2KCNH2
SCHEMBL5888082 0.82 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3TAS1R3TAS1R1
SCHEMBL5224404 0.82 HPGD (0.51) SLC6A2SLC6A4SLC6A3KCNH2TP53
SCHEMBL5887877 0.82 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817281-A1 N- [(3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS Pfizer Limited (GB) 2007-08-15 — — EP disclosed
US-7122683-B2 Amides useful as monoamine re-uptake inhibitors PFIZER INC. (US) 2006-10-17 — — US disclosed
WO-2006056884-A1 N- [ (3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS PFIZER LIMITED (GB) 2006-06-01 — — WO disclosed
US-20060111429-A1 Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting PFIZER INC 2006-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111429-A1 Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting ADRB3, AOC3, HRH4 SLC6A2 33/4885SLC6A4 49/4885SLC6A3 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.